trimethidinium profile

Trimethidinium is a bis-quaternary ammonium compound that has been studied for its potential therapeutic effects in a variety of conditions. It is a potent inhibitor of the enzyme acetylcholinesterase, which plays a role in the breakdown of acetylcholine, a neurotransmitter involved in muscle contraction and other functions. Trimethidinium has been shown to improve muscle strength and function in animal models of muscular dystrophy. It has also been investigated for its potential use in the treatment of Alzheimer's disease, Parkinson's disease, and other neurological disorders. However, trimethidinium has not yet been approved for clinical use in humans. Further research is needed to determine its safety and efficacy in humans.'

trimethidinium: RN given refers to parent cpd; camphonium refers to the di-I salt [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	26484
CHEMBL ID	1708232
CHEBI ID	135103
SCHEMBL ID	317314
MeSH ID	M0105898

Synonyms (24)

Synonym
trimethidinium
NCGC00160374-01
CHEBI:135103
AKOS000541703
unii-fz7142tv3j
2624-50-2
fz7142tv3j ,
3-azoniabicyclo(3.2.1)octane, 1,3,8,8-tetramethyl-3-(3-(trimethylammonio)propyl)-
CHEMBL1708232
trimethidenium
trimethidinium cation
trimethidinium ion
AKOS021983359
AB01330157-02
SCHEMBL317314
DTXSID0048424
NCGC00160374-02
1,3,8,8-tetramethyl-3-[3-(trimethylazaniumyl)propyl]-3-azabicyclo[3.2.1]octan-3-ium
1,3,8,8-tetramethyl-3-(3-(trimethylammonio)propyl)-3-azoniabicyclo(3.2.1)octane
NCGC00160374-03
STL552870
(5s)-1,3,8,8-tetramethyl-3-[3-(trimethylammonio)propyl]-3-azoniabicyclo[3.2.1]octane
Q27278327
trimethyl-[3-(1,3,8,8-tetramethyl-3-azoniabicyclo[3.2.1]octan-3-yl)propyl]azanium

Drug Classes (1)

Class	Description
azepanes
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	1.2589	0.0355	20.9770	89.1251	AID504332
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	0.1438	0.0056	12.3677	36.1254	AID624032
histone acetyltransferase KAT2A isoform 1	Homo sapiens (human)	Potency	22.3872	0.2512	15.8432	39.8107	AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay ID	Title	Year	Journal	Article
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (66.67)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.53 (24.57)
Research Supply Index	1.79 (2.92)
Research Growth Index	4.32 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.53)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
reserpine Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.	1.93	1	0	alkaloid ester; methyl ester; yohimban alkaloid	adrenergic uptake inhibitor; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; first generation antipsychotic; plant metabolite; xenobiotic
pempidine Pempidine: A nicotinic antagonist most commonly used as an experimental tool. It has been used as a ganglionic blocker in the treatment of hypertension but has largely been supplanted for that purpose by more specific drugs.	6.93	1	0	piperidines

Condition	Indicated	Relationship Strength	Studies	Trials
Blood Pressure, High [description not available]	0	2.34	2	0
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	0	7.34	2	0

trimethidinium

Description